Last 12 months
Inside the activity.
1 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2022 Filed Mar 4, 2022 21:09 UTC |
Spurr RobertU.S. President-Pharma Business
|
SaleCommon Shares, No Par Value | 1,595 | $23.37 | $37,275.15 |
DisclosureSEC source: 0001127602-22-008251 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,394 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:29 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
SaleCommon Shares, No Par Value | 6,338 | $23.82 | $150,971.16 |
DisclosureSEC source: 0000899243-22-008830 · doc4.xml · nonDerivative · entry 5 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,179 F6 · shares: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 27, 2021. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:38 UTC |
PAPA JOSEPH CDirector · Chairman & CEO
|
Tax withholdingCommon Shares, No Par Value | 5,115 | $24.06 | $123,066.90 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 5 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,795 F6 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:12 UTC |
APPIO THOMASCEO, Pharma Business
|
Exercise / conversionRestricted Share Units · Derivative | 24,292 | $24.35 Strike: $24.35 | $591,510.20 |
DisclosureSEC source: 0000899243-22-008826 · doc4.xml · derivative · entry 6 APPIO THOMAS · CIK 0001683323 · CEO, Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:12 UTC |
APPIO THOMASCEO, Pharma Business
|
GrantRestricted Share Units · Derivative | 24,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008826 · doc4.xml · derivative · entry 5 APPIO THOMAS · CIK 0001683323 · CEO, Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 24,292 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis F2 · price: Each PSU converts into Common Shares on a one-for-one basis F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:12 UTC |
APPIO THOMASCEO, Pharma Business
|
Tax withholdingCommon Shares, No Par Value | 2,402 | $24.35 | $58,488.70 |
DisclosureSEC source: 0000899243-22-008826 · doc4.xml · nonDerivative · entry 4 APPIO THOMAS · CIK 0001683323 · CEO, Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,141 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:12 UTC |
APPIO THOMASCEO, Pharma Business
|
Tax withholdingCommon Shares, No Par Value | 8,782 | $24.35 | $213,841.70 |
DisclosureSEC source: 0000899243-22-008826 · doc4.xml · nonDerivative · entry 2 APPIO THOMAS · CIK 0001683323 · CEO, Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,735 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:12 UTC |
APPIO THOMASCEO, Pharma Business
|
Exercise / conversionCommon Shares, No Par Value | 24,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008826 · doc4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · CEO, Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC |
PAPA JOSEPH CDirector · Chairman & CEO
|
Exercise / conversionRestricted Share Units · Derivative | 208,231 | $24.35 Strike: $24.35 | $5,070,424.85 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · derivative · entry 7 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC |
PAPA JOSEPH CDirector · Chairman & CEO
|
GrantRestricted Share Units · Derivative | 208,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · derivative · entry 6 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 208,231 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis F2 · price: Each PSU converts into Common Shares on a one-for-one basis F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC |
PAPA JOSEPH CDirector · Chairman & CEO
|
Tax withholdingCommon Shares, No Par Value | 13,206 | $24.35 | $321,566.10 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 4 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,910 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC |
PAPA JOSEPH CDirector · Chairman & CEO
|
Tax withholdingCommon Shares, No Par Value | 100,351 | $24.35 | $2,443,546.85 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,139,299 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:38 UTC |
PAPA JOSEPH CDirector · Chairman & CEO
|
Exercise / conversionCommon Shares, No Par Value | 208,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,239,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:29 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Exercise / conversionRestricted Share Units · Derivative | 17,350 | $24.35 Strike: $24.35 | $422,472.50 |
DisclosureSEC source: 0000899243-22-008830 · doc4.xml · derivative · entry 7 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:29 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
GrantRestricted Share Units · Derivative | 17,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008830 · doc4.xml · derivative · entry 6 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 17,350 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis F2 · price: Each PSU converts into Common Shares on a one-for-one basis F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:29 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Shares, No Par Value | 1,716 | $24.35 | $41,784.60 |
DisclosureSEC source: 0000899243-22-008830 · doc4.xml · nonDerivative · entry 4 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,517 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:29 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Shares, No Par Value | 6,233 | $24.35 | $151,773.55 |
DisclosureSEC source: 0000899243-22-008830 · doc4.xml · nonDerivative · entry 2 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,755 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:29 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Exercise / conversionCommon Shares, No Par Value | 17,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008830 · doc4.xml · nonDerivative · entry 1 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC |
Spurr RobertDirector · U.S. President-Pharma Business
|
Exercise / conversionRestricted Share Units · Derivative | 15,615 | $24.35 Strike: $24.35 | $380,225.25 |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · derivative · entry 6 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC |
Spurr RobertDirector · U.S. President-Pharma Business
|
GrantRestricted Share Units · Derivative | 15,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · derivative · entry 5 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 15,615 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis F2 · price: Each PSU converts into Common Shares on a one-for-one basis F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC |
Spurr RobertDirector · U.S. President-Pharma Business
|
Tax withholdingCommon Shares, No Par Value | 1,651 | $24.35 | $40,201.85 |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · nonDerivative · entry 4 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,989 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC |
Spurr RobertDirector · U.S. President-Pharma Business
|
Tax withholdingCommon Shares, No Par Value | 5,646 | $24.35 | $137,480.10 |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · nonDerivative · entry 2 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,268 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:08 UTC |
Spurr RobertDirector · U.S. President-Pharma Business
|
Exercise / conversionCommon Shares, No Par Value | 15,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:06 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Exercise / conversionRestricted Share Units · Derivative | 24,292 | $24.35 Strike: $24.35 | $591,510.20 |
DisclosureSEC source: 0000899243-22-008818 · doc4.xml · derivative · entry 6 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 24,292 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:06 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Tax withholdingCommon Shares, No Par Value | 3,006 | $24.35 | $73,196.10 |
DisclosureSEC source: 0000899243-22-008818 · doc4.xml · nonDerivative · entry 4 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,005 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:06 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Tax withholdingCommon Shares, No Par Value | 2,743 | $24.35 | $66,792.05 |
DisclosureSEC source: 0000899243-22-008818 · doc4.xml · nonDerivative · entry 3 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,011 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:06 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Tax withholdingCommon Shares, No Par Value | 10,279 | $24.35 | $250,293.65 |
DisclosureSEC source: 0000899243-22-008818 · doc4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,754 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:06 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Exercise / conversionCommon Shares, No Par Value | 24,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008818 · doc4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:01 UTC |
Munsch FrederickSVP, Controller and CAO
|
Exercise / conversionRestricted Share Units · Derivative | 3,330 | $24.35 Strike: $24.35 | $81,085.50 |
DisclosureSEC source: 0000899243-22-008808 · doc4.xml · derivative · entry 6 Munsch Frederick · CIK 0001864367 · SVP, Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:01 UTC |
Munsch FrederickSVP, Controller and CAO
|
GrantRestricted Share Units · Derivative | 3,330 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008808 · doc4.xml · derivative · entry 5 Munsch Frederick · CIK 0001864367 · SVP, Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 3,330 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis F2 · price: Each PSU converts into Common Shares on a one-for-one basis F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:01 UTC |
Munsch FrederickSVP, Controller and CAO
|
Tax withholdingCommon Shares, No Par Value | 334 | $24.35 | $8,132.90 |
DisclosureSEC source: 0000899243-22-008808 · doc4.xml · nonDerivative · entry 4 Munsch Frederick · CIK 0001864367 · SVP, Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,790 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:01 UTC |
Munsch FrederickSVP, Controller and CAO
|
Tax withholdingCommon Shares, No Par Value | 1,318 | $24.35 | $32,093.30 |
DisclosureSEC source: 0000899243-22-008808 · doc4.xml · nonDerivative · entry 2 Munsch Frederick · CIK 0001864367 · SVP, Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,430 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:01 UTC |
Munsch FrederickSVP, Controller and CAO
|
Exercise / conversionCommon Shares, No Par Value | 3,330 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008808 · doc4.xml · nonDerivative · entry 1 Munsch Frederick · CIK 0001864367 · SVP, Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:00 UTC |
Eldessouky SamEVP & Chief Financial Officer
|
Exercise / conversionRestricted Share Units · Derivative | 8,674 | $24.35 Strike: $24.35 | $211,211.90 |
DisclosureSEC source: 0000899243-22-008806 · doc4.xml · derivative · entry 6 Eldessouky Sam · CIK 0001558676 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 0 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:00 UTC |
Eldessouky SamEVP & Chief Financial Officer
|
GrantRestricted Share Units · Derivative | 8,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008806 · doc4.xml · derivative · entry 5 Eldessouky Sam · CIK 0001558676 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 8,674 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis F2 · price: Each PSU converts into Common Shares on a one-for-one basis F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:00 UTC |
Eldessouky SamEVP & Chief Financial Officer
|
Tax withholdingCommon Shares, No Par Value | 918 | $24.35 | $22,353.30 |
DisclosureSEC source: 0000899243-22-008806 · doc4.xml · nonDerivative · entry 4 Eldessouky Sam · CIK 0001558676 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,697 F5 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:00 UTC |
Eldessouky SamEVP & Chief Financial Officer
|
Tax withholdingCommon Shares, No Par Value | 3,102 | $24.35 | $75,533.70 |
DisclosureSEC source: 0000899243-22-008806 · doc4.xml · nonDerivative · entry 2 Eldessouky Sam · CIK 0001558676 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,429 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs. Read SEC document |
| February 27, 2022 Filed Mar 3, 2022 02:00 UTC |
Eldessouky SamEVP & Chief Financial Officer
|
Exercise / conversionCommon Shares, No Par Value | 8,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008806 · doc4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. F2 · price: Each PSU converts into Common Shares on a one-for-one basis Read SEC document |
| February 26, 2022 Filed Mar 3, 2022 02:12 UTC |
APPIO THOMASCEO, Pharma Business
|
Tax withholdingCommon Shares, No Par Value | 2,192 | $24.35 | $53,375.20 |
DisclosureSEC source: 0000899243-22-008826 · doc4.xml · nonDerivative · entry 3 APPIO THOMAS · CIK 0001683323 · CEO, Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,543 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| February 26, 2022 Filed Mar 3, 2022 02:38 UTC |
PAPA JOSEPH CDirector · Chairman & CEO
|
Tax withholdingCommon Shares, No Par Value | 13,183 | $24.35 | $321,006.05 |
DisclosureSEC source: 0000899243-22-008833 · doc4.xml · nonDerivative · entry 3 PAPA JOSEPH C · CIK 0001242215 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,126,116 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| February 26, 2022 Filed Mar 3, 2022 02:29 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Shares, No Par Value | 1,522 | $24.35 | $37,060.70 |
DisclosureSEC source: 0000899243-22-008830 · doc4.xml · nonDerivative · entry 3 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,233 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| February 26, 2022 Filed Mar 3, 2022 02:08 UTC |
Spurr RobertDirector · U.S. President-Pharma Business
|
Tax withholdingCommon Shares, No Par Value | 1,628 | $24.35 | $39,641.80 |
DisclosureSEC source: 0000899243-22-008822 · doc4.xml · nonDerivative · entry 3 Spurr Robert · CIK 0001543795 · Director · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,640 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| February 26, 2022 Filed Mar 3, 2022 02:01 UTC |
Munsch FrederickSVP, Controller and CAO
|
Tax withholdingCommon Shares, No Par Value | 306 | $24.35 | $7,451.10 |
DisclosureSEC source: 0000899243-22-008808 · doc4.xml · nonDerivative · entry 3 Munsch Frederick · CIK 0001864367 · SVP, Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,124 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| February 26, 2022 Filed Mar 3, 2022 02:00 UTC |
Eldessouky SamEVP & Chief Financial Officer
|
Tax withholdingCommon Shares, No Par Value | 814 | $24.35 | $19,820.90 |
DisclosureSEC source: 0000899243-22-008806 · doc4.xml · nonDerivative · entry 3 Eldessouky Sam · CIK 0001558676 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,615 F4 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units ("RSUs"). Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:36 UTC |
Spurr RobertU.S. President-Pharma Business
|
SaleCommon Shares, No Par Value | 3,251 | $25.02 | $81,340.02 |
DisclosureSEC source: 0001127602-22-005469 · form4.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,299 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| February 14, 2022 Filed Mar 3, 2022 02:06 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
GrantRestricted Share Units · Derivative | 24,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-008818 · doc4.xml · derivative · entry 5 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares, No Par Value · 24,292 shares Expires 2022-02-27 F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis. F2 · price: Each PSU converts into Common Shares on a one-for-one basis. F1 · derivative.exercise_date: Reflects the vesting and conversion of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person, into common shares, no par value ("Common Shares") of the Issuer. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:55 UTC |
Spurr RobertU.S. President-Pharma Business
|
SaleCommon Shares, No Par Value | 3,251 | $26.63 | $86,574.13 |
DisclosureSEC source: 0000950103-22-000900 · dp165456_4-spurr.xml · nonDerivative · entry 1 Spurr Robert · CIK 0001543795 · U.S. President-Pharma Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,550 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2021. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:17 UTC |
DE SCHUTTER RICHARD UDirector
|
GrantCommon Shares, No Par Value | 1,245 | $27.61 | $34,374.45 |
DisclosureSEC source: 0001127602-22-000105 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,588 F1 · shares: Reflects Restricted Share Units, each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:16 UTC |
WECHSLER AMY BDirector
|
GrantCommon Shares, No Par Value | 249 | $27.61 | $6,874.89 |
DisclosureSEC source: 0001127602-22-000102 · form4.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,054 F1 · shares: Reflects Restricted Share Units, each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:14 UTC |
ROBERTSON RUSSEL CDirector
|
GrantCommon Shares, No Par Value | 1,380 | $27.61 | $38,101.80 |
DisclosureSEC source: 0001127602-22-000097 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,585 F1 · shares: Reflects Restricted Share Units, each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.